Jon Voutila

843 total citations
8 papers, 475 citations indexed

About

Jon Voutila is a scholar working on Molecular Biology, Cancer Research and Geriatrics and Gerontology. According to data from OpenAlex, Jon Voutila has authored 8 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Cancer Research and 1 paper in Geriatrics and Gerontology. Recurrent topics in Jon Voutila's work include MicroRNA in disease regulation (3 papers), Pluripotent Stem Cells Research (2 papers) and CRISPR and Genetic Engineering (2 papers). Jon Voutila is often cited by papers focused on MicroRNA in disease regulation (3 papers), Pluripotent Stem Cells Research (2 papers) and CRISPR and Genetic Engineering (2 papers). Jon Voutila collaborates with scholars based in United Kingdom, United States and Norway. Jon Voutila's co-authors include Nagy Habib, David C. Blakey, Matthew C. Catley, Alexandre J. Debacker, John J. Rossi, Pål Sætrom, Vikash Reebye, Pinelopi Andrikakou, Robert Habib and Hans E. Huber and has published in prestigious journals such as Oncogene, Molecular Therapy and Advances in experimental medicine and biology.

In The Last Decade

Jon Voutila

8 papers receiving 468 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jon Voutila United Kingdom 7 390 118 42 40 36 8 475
Tuyen Nguyen United States 10 468 1.2× 112 0.9× 103 2.5× 32 0.8× 36 1.0× 14 623
Zhongxia Wang China 9 174 0.4× 55 0.5× 29 0.7× 42 1.1× 31 0.9× 21 304
Zhengfeng Wang China 9 213 0.5× 82 0.7× 41 1.0× 43 1.1× 30 0.8× 17 392
Doris Losert Austria 8 385 1.0× 103 0.9× 53 1.3× 38 0.9× 22 0.6× 11 487
Xiaoyong Luo China 9 214 0.5× 94 0.8× 20 0.5× 50 1.3× 24 0.7× 19 310
Jin-Ping Li Sweden 10 376 1.0× 40 0.3× 36 0.9× 22 0.6× 63 1.8× 15 571
Colton M. Miller United States 8 276 0.7× 29 0.2× 45 1.1× 36 0.9× 16 0.4× 11 370
Meng Lou China 13 328 0.8× 93 0.8× 54 1.3× 26 0.7× 32 0.9× 21 457
Leslie A. Morton United States 9 278 0.7× 100 0.8× 41 1.0× 95 2.4× 15 0.4× 11 400

Countries citing papers authored by Jon Voutila

Since Specialization
Citations

This map shows the geographic impact of Jon Voutila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Voutila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Voutila more than expected).

Fields of papers citing papers by Jon Voutila

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Voutila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Voutila. The network helps show where Jon Voutila may publish in the future.

Co-authorship network of co-authors of Jon Voutila

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Voutila. A scholar is included among the top collaborators of Jon Voutila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Voutila. Jon Voutila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Andrikakou, Pinelopi, Vikash Reebye, Daniel Vasconcelos, et al.. (2022). Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome. Nucleic Acid Therapeutics. 32(6). 486–496. 11 indexed citations
2.
Debacker, Alexandre J., Jon Voutila, Matthew C. Catley, David C. Blakey, & Nagy Habib. (2020). Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. Molecular Therapy. 28(8). 1759–1771. 235 indexed citations
3.
Reebye, Vikash, Kai‐Wen Huang, Vivian Lin, et al.. (2018). Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene. 37(24). 3216–3228. 73 indexed citations
4.
Zhao, Xiaoyang, et al.. (2017). Treatment of Liver Cancer by C/EBPA saRNA. Advances in experimental medicine and biology. 983. 189–194. 9 indexed citations
5.
Voutila, Jon, Vikash Reebye, Thomas C. Roberts, et al.. (2017). Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer. Molecular Therapy. 25(12). 2705–2714. 85 indexed citations
6.
Gschweng, Eric H., Agustin Vega-Crespo, Jon Voutila, et al.. (2015). Putative Immunogenicity Expression Profiling Using Human Pluripotent Stem Cells and Derivatives. Stem Cells Translational Medicine. 4(2). 136–145. 4 indexed citations
7.
Voutila, Jon, Pål Sætrom, Paul J. Mintz, et al.. (2012). Gene Expression Profile Changes After Short-activating RNA-mediated Induction of Endogenous Pluripotency Factors in Human Mesenchymal Stem Cells. Molecular Therapy — Nucleic Acids. 1. e35–e35. 29 indexed citations
8.
Pellegrini, Matteo, Jerry C. Cheng, Jon Voutila, et al.. (2008). Expression profile of CREB knockdown in myeloid leukemia cells. BMC Cancer. 8(1). 264–264. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026